OVID Ovid Therapeutics Inc.

+0.02  (+1%)
Previous Close 1.95
Open 1.95
Price To Book 1.97
Market Cap 76136347
Shares 38,647,892
Volume 52,125
Short Ratio
Av. Daily Volume 220,358

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 2H 2019.
OV101 (gaboxadol)
Fragile X syndrome
Phase 1/2 data released December 17, 2018 met primary endpoint of safety and tolerability.
Developmental and Epileptic Encephalopathies (dEE)
Phase 3 trial planned for 2H 2019.
Adolescents with Angelman syndrome
Phase 2 trial initiation announced September 24, 2018.
Developmental and Epileptic Encephalopathies (dEE) - younger patient population
Phase 1b/2a enrolment to be completed 2H 2019.
TAK-935/OV935 - ARCADE
CDKL5 Deficiency

Latest News

  1. Ovid Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
  2. Ovid Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference on Monday, March 11
  3. Why A Secondary Offering Is Often Negative For Stocks
  4. Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
  5. The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering
  6. Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
  7. Zynerba Stock Is Marijuana-Adjacent Play Worth a Look
  8. How Much Of Ovid Therapeutics Inc. (NASDAQ:OVID) Do Insiders Own?
  9. Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies
  10. Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
  11. Ovid Therapeutics Announces OV935/TAK-935 Presentations at the American Epilepsy Society 72nd Annual Meeting
  12. Granite Point Capital’s Returns, AUM, and Holdings
  13. Ovid Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27
  14. Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress
  15. OVID THERAPEUTC Sees Hammer Chart Pattern: Time to Buy?